Novimmune unit nabs Takeda milestone payment for hemophilia work

Takeda HQ
The original deal with Light Chain Bioscience, a unit of Swiss biotech Novimmune, was penned with Shire in 2017 but now continues under new owner Takeda. (Takeda)

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda Pharmaceutical.

The competitive hemophilia A market has seen a lot of intensity in R&D in the past few years, with a focus now on gene therapies. Light Chain Bioscience is focusing its efforts on bispecifics as it hopes to challenge Roche’s bleeding drug Hemlibra, also a bispecific that works as a factor IXa- and factor X-directed antibody. It’s seen top sales estimates of $5 billion a year at peak.

The biotech’s milestone was “achieved upon the successful completion of the discovery phase and designation by Takeda of undisclosed bispecific antibodies as clinical development candidates with approval to advance to IND-enabling studies,” the company said, though extra details and money paid were not being shared.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The collab is designed to create bispecific antibodies with factor VIII mimetic activity for the treatment of hemophilia A patients.

The original pact was signed under Shire, which has since been snapped up by the Japanese Big Pharma. Under the 2017 deal, Shire (now Takeda) nabbed rights to develop and sell the drug. The endgame is to create a product that is better and safer than the current factor class.

Financials were not disclosed.

The European company has been developing a platform for making fully human, bispecific antibodies and has several in-house programs targeting tumor-associated antigens and immune system checkpoint protein CD47. The biotech and Shire first struck an R&D collaboration back in 2015.

Suggested Articles

Wedding Five Prime Therapeutics’ cabiralizumab to Bristol-Myers Squibb’s checkpoint inhibitor Opdivo has proved to be a bust in pancreatic cancer.

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.